allergy indications - Heel BHI
allergy indications - Heel BHI
allergy indications - Heel BHI
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>allergy</strong> <strong>indications</strong><br />
Addressing your patients needs safely and effectively
inTroducTion<br />
Allergies pose major health problems. Not only does<br />
disease-like allergic rhinitis affect 20 to 40 million people<br />
annually, it also results in an accumulative 3.8 million<br />
lost work and school days. The wide coverage of anti-<br />
allergic medicine in the media and on supermarket shelves<br />
also alludes to the widespread impact of this condition.<br />
The allergic response<br />
Allergy represents an inappropriate reaction of an organism to a mostly innocuous<br />
substance. Allergens could be seasonal, such as mold, grasses, trees and pollens, as<br />
well as perennial (through the year), such as dust mites and animal dander. Irritants, like<br />
cigarette smoke and diesel exhaust fumes may promote the allergic response, but are not<br />
allergens in themselves. It is important to note that for the immune system to develop an<br />
allergic response, the substance needs to possess a peptide sequence or an amino acid<br />
sequence.<br />
Why is the immune system so vulnerable today?<br />
As with the development of all diseases, the development of allergies depends on three<br />
factors: genetic predisposition, environmental influences and a trigger.<br />
The genetic predisposition has been well studied in patients with allergies. Experiments<br />
conducted in the 1920’s already showed that if two parents were allergic, 50% of their<br />
offspring would be allergic, and even if one parent was allergic, 30% of thier offspring<br />
stood a chance to be allergic.<br />
The effects of environmental toxins have been mentioned, but it is also important to note<br />
that allergic mediators, such as histamine, are internal toxins and are cleared from the<br />
system through liver detoxification. If the liver is overloaded, or missing certain important<br />
co-factors, the patient will not be able to remove the histamine from the system, and<br />
will have more symptoms of <strong>allergy</strong>. If certain immunotoxic chemicals are not cleared<br />
from the body, and are stored in the matrix, they can contribute to an abnormal immune<br />
response. Detoxification and support of the detoxifying organs is an integral part of the<br />
homotoxicological approach to <strong>allergy</strong>.<br />
The cytokine environment in the tissues is also of special importance. It is well recognized<br />
now that patients with allergies have an immune response which, on a cellular level, is<br />
skewed towards a certain reaction, namely a TH2 response.<br />
Normally, T-helper cells circulate as T-0 cells, and depending on which antigen it is<br />
presented with (via the antigen presenting cells such as macrophages and dendritic cells)<br />
it will develop into a TH1 cell, TH2 or a TH3 cell (Figure 2).<br />
Fig. 1: The allergic response.<br />
Dust Mite<br />
The incidence of <strong>allergy</strong> is increasing and numerous factors have been postulated for<br />
this. People living in urban areas are more prone to allergic disease. Environmental<br />
factors, such as diesel exhaust fumes, and especially sulfur dioxide, as well as<br />
ozone and overcrowding have all been implicated in allergic disease. Environmental<br />
toxins like sulfur dioxide not only predispose the immune system to <strong>allergy</strong>, but also<br />
change the quality of the nasal mucosa so that it has a hyper-responsiveness towards<br />
allergens. It may also change the structure of an antigen-like pollen so that it becomes<br />
more allergenic.<br />
These cells secrete different<br />
messengers called cytokines,<br />
which will then generate the<br />
appropriate immune response.<br />
In the case of a virus or fungal<br />
infection, a TH1 response is<br />
preferred. TH1 will generate a<br />
cellular immune response via the<br />
secretion of the cytokines IFN<br />
gamma, Tumor Necrosis Factor<br />
IL-2<br />
IFN gamma<br />
TNF<br />
Inflammation<br />
DHEA<br />
TGF-ß<br />
Inhibition<br />
Cortisol<br />
IL-4, 13<br />
IL-5<br />
IL-10<br />
Allergy<br />
(TNF), and IL-1 to kill these invaders. Antibodies are made when TH2 cells are stimulated,<br />
as TH2 cells will activate plasma cells. The TH2 cells secrete other cytokins Interleukin 4, 5,<br />
10, and 13, apart from other cytokins. These cytokines are closely involved in the allergic<br />
response, as Interleukin 4 and 13 induce IgE formation, Interleukin 5 enhances the growth<br />
of eosinophils and Interleukin 10 promotes mast cell growth (See also the Immunology of<br />
Allergy).<br />
TH3 helper cells are regulatory T-cells and secrete mainly a cytokine called Transforming<br />
Growth Factor beta (TGF-ß), which is an anti-inflammatory that facilitates tissue repair, and<br />
may be able to restore the balance between TH1 and TH2.<br />
In healthy individuals there is a small daily oscillation between TH1 and TH2 cells, so that<br />
the body is always ready to respond in a certain fashion. It is a well known fact that allergic<br />
patients are slanted towards a TH2 response. Some patients are born with this skewed<br />
response, especially if they are allergic from birth. This means that the immune system<br />
will easily go down the TH2 pathway in response to antigens, and cause allergic reactions<br />
more easily.<br />
Fig. 2: TH1/TH2 balance.<br />
In Homotoxicology, we call this skewed response “regulation rigidity” and we should<br />
endeavor to restore the normal physiological oscillations between TH1 and TH2 cells.<br />
Traumeel has been shown to down regulate the pro-inflammatory cytokines, and to<br />
increase TGF-ß, and it is postulated to induce TH3 cells.
Infections with parasites and fungi can also promote the TH2 response. These organisms<br />
are mostly eliminated via a TH1 response, but they have developed a mechanism to escape<br />
this by pushing the immune system into the TH2 state via some of the surface proteins, like<br />
mannan, in the case of fungi. Allergy is often a concomitant finding in these diseases.<br />
The hygiene hypothesis is of particular interest, where it is postulated that the modern use<br />
of vaccines and antibiotics to ban banal disease (which mostly will mount a TH1 response),<br />
results in a skewed immune response towards the allergic (TH2) side.<br />
In Homotoxicology, we recognize both the effects of toxins on the organism (in this<br />
case the immune system), as well as the dangers of suppressing banal disease in the<br />
development of chronic disease and regulation rigidity. The Homotoxicological approach<br />
to <strong>allergy</strong> will focus on three points:<br />
• Drainage and detoxification<br />
• Treatment of the regulation rigidity of the immune system<br />
• Treatment of the symptoms of allergic disease.<br />
These three points cause the most distress in patients.<br />
The allergic response itself is depicted in the diagram below (Figure 1), and consists of<br />
three phases: Phase I: sensitization or priming, Phase II: the Early Allergic Response (EAR),<br />
and Phase III: the Late Allergic Response (LAR).<br />
Allergy is never seen on the first exposure to an antigen, because the allergic response<br />
is a type-I (anaphylactic) response which is mediated by IgE antibodies, and cells such<br />
as macrophages, mast cells, T-helper cells (especially TH2 cells), and eosinophils. The<br />
first sensitization occur and that the mast cell gets primed with IgE, which is specific for<br />
that allergen.<br />
The immunology of The allergic response<br />
1. sensitization:<br />
It may take up to 4 years for the primed mast cells to reach a critical mass for a specific<br />
antigen in a region in order to illicit an allergic response to that antigen. It is important to note<br />
that an allergic response may also occur without apparent previous exposure to an antigen,<br />
such as penicillin. This is due to cross allergies. The priming or sensitization of the immune<br />
system may have taken place via mold in the environment, which has an antigenic similarity<br />
to penicillin, and upon exposure to penicillin (a mold) for the first time, the patient may then<br />
get an allergic reaction. Cross allergies also exist between food and environmental allergens.<br />
For instance, grass pollens cross-react with<br />
tomatoes, and seeds of legumes such as<br />
peas and beans, and grains while natural<br />
latex cross reacts with bananas, avocados<br />
and grains. Therefore, a patient eating a lot<br />
of bananas may suddenly develop an <strong>allergy</strong><br />
to latex gloves.<br />
2. The early allergic response (ear)<br />
This takes place in the first 2-20 minutes after re-exposure to the antigen and in the<br />
presence of enough mast cells primed with IgE to react to that specific antigen. The<br />
mediators, such as histamine, increase vascular permeability and an influx of fluid.<br />
Leukotrines and prostaglandins cause inflammation. Chemo attractants are responsible for<br />
the recruitment of other immune cells, like basophils. The clinical result is itching, sneezing<br />
and bronchospasm.<br />
3. The late allergic response (lar)<br />
The Late Allergic Response is mediated via the cytokines from the products of the mast<br />
cells and TH2 cells, this develops in 4-10 hours after re-exposure. LAR involves the<br />
attraction of immune cells and also the maturation of the aforementioned cells. IL5 (from<br />
the mast cell and TH2 cell) can induce the growth of eosinophils, which are the main cells<br />
associated with the Late Allergic Response.<br />
The eosinophils de-granulate and secrete a number of substances, notably major basic<br />
protein and other substances like eosinophil derived neurotoxin, and peroxides. This will<br />
cause tremendous inflammation, which is the key characteristic of chronic <strong>allergy</strong>. The Late<br />
Allergic Response is responsible for the severity of asthma and is the component that is<br />
treated by corticosteroids. It is also the hallmark of diseases such as Chronic Eosinophilic<br />
Allergic Sinusitis where the response to a fungus is that of an eosinophilic infiltration,<br />
which eventually will give rise to destruction of the mucosa via the major basic protein<br />
(Figure 1).<br />
homoToxicology and <strong>allergy</strong><br />
According to the theory of Homotoxicology, disease follows the body’s inability<br />
to maintain homeostasis by regulation in the face of a toxin or other aggressor.<br />
In this case, the internal toxin is histamine and the dysregulation is the skewed<br />
immune response.<br />
The actions of histamine upon various tissues can be followed quite well in the body, and<br />
offer one of the best examples of a phenomenon called vicariation. Histamine in its different<br />
isoforms is active in various tissues like the skin, the mucosal membranes of the nose<br />
and lung, as well as in the gastric mucosa, the brain, and even the heart. It is involved in<br />
allergic rhinitis in the nose, asthma in the lung, eczema on the skin, ulceration in the gastric<br />
mucosa and also plays a part in myocardial infarction.<br />
Reckeweg postulated from the work of Constantine Hering and others, that if the normal<br />
regulatory mechanisms are suppressed or not successful, toxins such as histamine will<br />
cause disease in the body from the outside, inward, or from superficial embryological<br />
tissues to deeper ones. This is depicted on the Six-Phase Table of Homotocicology and is<br />
called progressive vicariation if it goes deeper and to the right on the table, and regressive<br />
vicariation if it moves toward more superficial tissues and the left of the table.
If superficial eczema is suppressed by topical cortisone, it<br />
may shift to a deeper tissue such as the lungs, and asthma<br />
may occur. It is well known in practice that in patients<br />
where both co-exist, the eczema gets worse when the<br />
asthma gets better, or reversed. In a patient with asthma,<br />
the development of eczema is seen as a regressive<br />
vicariation, and is welcomed rather than suppressed.<br />
Suppression will result in progressive vicariation to<br />
deeper tissues and into phases towards the right of the biological division, such as the<br />
impregnation phase (asthma). Suppression of disease on the skin may also vicariate<br />
to other tissues like the gastric mucosa and may lead to development of gastritis or<br />
ulcers as well. In Homotoxicology, an attempt is always made to regulate (get the body<br />
to balance physiologically), rather than to suppress the symptom.<br />
The homotoxicological approach is depicted in Figures 4 and 7 and employs the three<br />
pronged approach of symptomatic support, not suppression. Treating the allergic terrain<br />
is achieved by supporting the detoxifying organs, especially the liver and the matrix, as<br />
well as immune-regulation (via the down-regulation of inflammatory mediators) and the<br />
induction of TH3 regulatory cells.<br />
The symptomatic treatment is different for the different allergic diseases, but the<br />
detoxification and the regulation of the allergic response is the same.<br />
eczema:<br />
Eczema is a difficult condition to treat and is often treated with topical steroids<br />
which, from a homotoxicological perspective, may result in deeper disease such<br />
as asthma (Figure 5).<br />
Eczema may present with a wide variety of clinical pictures, and according to the drug<br />
pictures of the various homeopathic constituents in the homotoxicological remedies,<br />
one can choose a specific product for each type (Figure 6-7). The liver and skin has<br />
a special relationship as they have the same detoxification mechanisms. Histamine is<br />
broken down by the P450 system active in both tissues, and if the liver is overloaded,<br />
the histamine can be active in the skin as well. Liver drainage is very important in all<br />
skin diseases.<br />
allergic rhinitis:<br />
This debilitating condition can be treated by biological medicine, and typically, the<br />
patient is less allergic every new season, i.e. each allergic season is better than<br />
the previous one, even if one treats only during the <strong>allergy</strong> season. The regulatory<br />
treatment will have a longer and accumulative effect. In seasonal allergies,<br />
treatment should be started at least six weeks before onset of the <strong>allergy</strong> season.<br />
asthma:<br />
The six-phase Table - allergies and applicaTion of Therapy (abridged)<br />
Bronchial asthma has become the most common cause for hospitalization of children in<br />
the United States. In regards to asthma, treatment should be aimed at all three components<br />
leading to the obstruction in the airways: bronchospasm, mucous plugs and inflammation<br />
(Figure 7). In Homotoxicology, Tartephedreel ® and Engystol ® are aimed at the bronchospasm,<br />
while Traumeel treats the inflammation. Bronchalis-<strong>Heel</strong> ® treats the mucous plugs and can<br />
be left out if the patient does not have a lot of sticky phlegm. In conventional treatment,<br />
the bronchodilators will treat the bronchospasm, but the corticosteroid will treat the late<br />
response (inflammation). This is why cortisone will not give immediate relief in asthma, but<br />
a bronchodilator will. This is also the reason to wean a patient off the bronchodilator first.<br />
Weaning of patients off conventional therapy is a slow process and may take up to a year.<br />
Weaning should only be attempted after the simultaneous treatment with the conventional<br />
and the Homotoxicological therapy continues for awhile, as some regulation must be<br />
possible before the conventional support is withdrawn. A possible schedule is proposed in<br />
Figure 3, but it is important to note that the response may differ from patient to patient. The<br />
clinical picture, as well as the peak expiratory flow rate, must be monitored closely, and the<br />
treatment adjusted. The patient may need to stay on conventional treatment longer.<br />
H u m o r a l P H a s e s m at r i x P H a s e s C e l l u l a r P H a s e s<br />
organ system excretion phases inflammation phases deposition phases impregnation phases degeneration phases dedifferentiation phases<br />
Tissue damage No enzyme damage; Excretion principle; Natural healing tendency Enzyme damage; Compensation principle; Chronic Diseases<br />
skin Episodes of sweating Acute eczema Naevi Allergy, chronic eczema,<br />
urticaria<br />
Scleroderma Melanoma<br />
respiratory<br />
Tract<br />
gastrointestinal<br />
system<br />
Cough, expectoration Bronchitis, acute sinusitis Nasal polyps Asthma, allergic rhinitis Bronchiectasia, emphysema,<br />
eosinophilic rhinitis<br />
Heartburn Gastroenteritis, gastritis Hyperplastic gastritis Food <strong>allergy</strong> Atrophic gastritis, liver<br />
cirrhosis<br />
blood Reticulocytosis Leucocytosis, suppuration Polycythaemia,<br />
thrombocytosis<br />
lymph system Lymphedema Lymphangitis, tonsillitis,<br />
lymphadenitis<br />
immune system Susceptibility to infection Weak immune system,<br />
acute infection<br />
Weeks 1-12 Weeks 12-18 Weeks 18-24 Weeks 24-30 Weeks 30-36 Weeks 36-42<br />
homotoxicology Symptomatic + Symptomatic Symptomatic + Symptomatic Symptomatic + Symptomatic<br />
Regulation<br />
Regulation<br />
Regulation<br />
steroid Full dose Full dose Full dose Half dose Try to stop/ Try to stop/<br />
half dose half dose<br />
long acting<br />
bronchodilator<br />
Full dose Half dose Stop<br />
short acting At hand for At hand for At hand for At hand for At hand for At hand for<br />
bronchodilator acute need acute need acute need acute need acute need acute need<br />
Fig. 3: Proposed schedule for the weaning of conventional medicine in asthma patients.<br />
Symptomatic<br />
treatment<br />
• Eczema<br />
• Asthma<br />
• Allergic Rhinitis<br />
• Allergic Conjunctivitis<br />
Lymph-node swelling Insufficiency of the lymph<br />
system<br />
Weak reactions Autoimmune disease,<br />
immunodeficiency, chronic<br />
infections<br />
Aggregation disturbance Anemia, thrombocytopenia Leukemia<br />
Bronchial carcinoma<br />
Stomach cancer, colon<br />
cancer<br />
Fibrosis Lymphoma, Hodgkin-/ non-<br />
Hodgkin-lymphoma<br />
AIDS Slow reactions<br />
The six-phase table is a field matrix reflecting medical experience based on careful observation and empirical learning. It is a phase-by-phase arrangement of disorders with no direct relationship between them. No causal pathogenetic link between disorders<br />
can be inferred. The structure of the table makes it suitable for developing a prediction system giving a better assessment of the possibilities for a vicariation effect. © 2000 by Biologische Heilmittel <strong>Heel</strong> GmbH.<br />
biological division<br />
Allergy<br />
Treating the<br />
allergic terrain<br />
Detoxification<br />
and drainage •<br />
Immunomodulation •<br />
Stimulating tissue<br />
metabolism •<br />
Fig. 4: Homotoxicological approach to <strong>allergy</strong>.
egulaTory TreaTmenT<br />
Drainage:<br />
liver<br />
Hepeel<br />
Hepar compositum ®<br />
matrix:<br />
Galium-<strong>Heel</strong><br />
Pulsatilla compositum<br />
Thyreoidea compositum ® (Rx)<br />
Lymphomyosot ®<br />
Fig. 5: Eczema cross-section.<br />
Treating the allergic terrain:<br />
immunomodulation<br />
Traumeel ®<br />
Cutis compositum ®<br />
Mucosa compositum ®<br />
Tissue metabolism (catalyst)<br />
Coenzyme compositum<br />
Ubichinon compositum ®<br />
Glyoxal compositum ®<br />
sympTomaTic TreaTmenT<br />
Fig. 6: Symptomatic treatment of eczema.<br />
product Type of eczema<br />
Graphites Homaccord Weepy eczema with honey<br />
colored discharge and<br />
crusting. Also eczema around<br />
ears and head.<br />
Sulphur-<strong>Heel</strong> Mixed types, vesicular, itchy,<br />
but with dry patches.<br />
Schwef-<strong>Heel</strong> Dry, intensively itchy, worse<br />
in heat.<br />
Lamioflur Intractable, often around the<br />
body orifices.<br />
Abropernol ® Dry, itchy, in the folds.<br />
Mezereum Homaccord Vesicular eczema with a<br />
tendency towards pustule<br />
formation.<br />
asthma<br />
Bronchalis-<strong>Heel</strong> •<br />
Tartephedreel •<br />
Engystol ® •<br />
Traumeel ® •<br />
allergic conjunctivitis •<br />
Oculoheel ®<br />
<strong>BHI</strong> Hayfever (Luffeel ® )<br />
allergic rhinitis •<br />
<strong>BHI</strong> Hayfever (Luffeel ® )<br />
Euphorbium Sinus Relief<br />
Naso-<strong>Heel</strong><br />
Fig. 7: Allergic Rhinitis, Conjunctivitis, and Asthma.
proTocols<br />
Table 1: Allergic Rhinitis and Conjunctivitis<br />
symptoms <strong>BHI</strong> Hayfever (Luffeel ® ),<br />
Oculoheel<br />
injecTion Therapy<br />
For the treatment of:<br />
Eczema<br />
Technique:<br />
Injection into point<br />
(Homeosiniatry)<br />
Remedies:<br />
Traumeel ®<br />
Lymphomyosot ®<br />
Points:<br />
DU 14<br />
LI 11<br />
SP 6<br />
SP 10<br />
ST 36<br />
H 7<br />
LI 11 •<br />
LI 4 •<br />
For the treatment of:<br />
Allergic rhinitis<br />
Technique:<br />
Injection into point<br />
(Homeosiniatry)<br />
Remedies:<br />
Traumeel ®<br />
Lymphomyosot ®<br />
Points:<br />
LI 4<br />
LI 20<br />
L 7<br />
ST 36<br />
SP 6<br />
GB 20<br />
mild to moderate moderate to severe<br />
ST 36 •<br />
ST 40 •<br />
<strong>BHI</strong> Hayfever (Luffeel ® ), Naso-<strong>Heel</strong><br />
(anosmia), Euphorbium Sinus Relief<br />
(polyps), Oculoheel<br />
Hepar compositum ® , Lymphomyosot ® ,<br />
Pulsatilla compositum<br />
drainage<br />
Allergic terrain<br />
Hepeel, Galium-<strong>Heel</strong>,<br />
Lymphomyosot<br />
immunomodulation Traumeel ® ,<br />
Mucosa compositum ®<br />
catalysts Coenzyme compositum Coenzyme compositum,<br />
Ubichinon compositum ®<br />
Traumeel ® , Mucosa compositum ®<br />
• Yin Tang<br />
• LI 20<br />
• CV 22<br />
• CV 21<br />
• SP 10<br />
• SP 6<br />
• CV 17<br />
• CV 4<br />
© 2005 <strong>Heel</strong> Inc. <strong>Heel</strong>, <strong>BHI</strong>, Homaccord, Abropernol, Cutis compositum, Engystol, Glyoxal compositum, Hepar compositum, Husteel, Lymphomyosot, Mezereum Homaccord,<br />
Mucosa compositum, Thyreoidea compositum, Traumeel, and Ubichinon compositum are all registered trademarks of Biologische Heilmittel <strong>Heel</strong> GmbH. No portion of this publication<br />
may be reproduced without written authorized permission. The contents of this brochure are for educational, informational, and product description purposes only. In no<br />
event shall <strong>Heel</strong> Inc. be liable for any special, indirect or consequential damages or any damages whatsoever resulting from the use of any information contained within. <strong>Heel</strong> Inc.<br />
assumes no responsibility for errors or omissions in any information provided in this brochure, nor does it warrant the accuracy or completeness of the information, text, graphics,<br />
or other items contained within these materials.<br />
• L 7<br />
• H 7<br />
Table 2: Asthma<br />
mild to moderate moderate to severe<br />
symptoms Tartephedreel, Husteel ® , Tartephedreel, Husteel<br />
Bronchalis-<strong>Heel</strong><br />
® ,<br />
Bronchalis-<strong>Heel</strong><br />
drainage Hepeel, Pulsatilla compositum,<br />
Lymphomyosot ®<br />
Hepar compositum, Lymphomyosot ® ,<br />
Thyreoidea compositum ® (Rx)<br />
immunomodulation Traumeel, Engystol<br />
Mucosa compositum ®<br />
Traumeel, Engystol, Mucosa compositum,<br />
Tonsilla compositum<br />
catalyst Coenzyme compositum,<br />
Ubichinon compositum ®<br />
Coenzyme compositum,<br />
Ubichinon compositum ®<br />
Intersperse with Glyoxal compositum ®<br />
Table 3: Eczema<br />
mild to moderate moderate to severe<br />
symptoms See Figure 6 on page 4 for<br />
specific type<br />
See table on page 4 for specific type<br />
drainage Hepeel, Galium-<strong>Heel</strong>,<br />
Lymphomyosot ® Hepar compositum<br />
, Pulsatilla<br />
compositum (After cortisone)<br />
® , Pulsatilla<br />
compositum, Thyreoidea compositum ® (Rx),<br />
Lymphomyosot ®<br />
immunomodulation Traumeel ® , Cutis<br />
Traumeel ® , Cutis compositum ®<br />
compositum ®<br />
catalyst Coenzyme compositum Coenzyme compositum,<br />
Ubichinon compositum ®<br />
C 7 •<br />
T 6 •<br />
Injection Technique:<br />
Injection into point (Homeosiniatry) should be 0.1ml<br />
each remedy with a half-inch, 30 gauge needle.<br />
3110010/1205/12000<br />
• GB 20<br />
• DU 14<br />
For the treatment of:<br />
Asthma<br />
Technique:<br />
Injection into point<br />
(Homeosiniatry)<br />
• BL 13<br />
Remedies:<br />
Traumeel ®<br />
Zeel ®<br />
Points:<br />
CV 4<br />
CV 17<br />
CV 21<br />
CV 22<br />
ST 36<br />
ST 40<br />
BL 13<br />
LI 4<br />
DU 14<br />
<strong>Heel</strong> Inc.<br />
Albuquerque, NM<br />
p: 1-800-621-7644<br />
f: 1-800-217-6934<br />
www.heelusa.com